Novel antiepileptic for Dravet syndrome

New extended release formulation and preclinical data set stage for Phase 1b Trial to start in mid-2017

Register for free to listen to this article
Listen with Speechify
MIAMI BEACH, Fla.—Biscayne Pharmaceuticals Inc. in October reported that a new scientific publication shows its lead compound BIS-001 can eliminate all seizures in the majority of animals in models of the type of epilepsy known as Dravet syndrome. BIS-001 is a clinical-stage, highly potent agent with a novel mechanism of action that is a synthetic form of huperzine A, an extract of a traditional Chinese medicine. Biscayne is initially developing BIS-001 for the treatment of children with Dravet syndrome and for adults with complex partial seizures.
The new studies assessed BIS-001 in mice who have the same SCN1A mutations seen in human Dravet syndrome and are subject to similar severe seizures. The studies were conducted in the Emory University laboratory of Dr. Andrew Escayg, who is a leading expert in the human and mouse genetics of neurological diseases. In these studies, BIS-001 completely eliminated seizures in the majority of treated animals at doses expected to be well tolerated and achievable in patients with a new extended-release formulation of BIS-001.
Importantly, the effects of BIS-001 were sustained over time, with high levels of antiseizure activity maintained during repeat dosing for up to 21 days, with no evidence of the tachyphylaxis, or diminishing efficacy, that can be seen with other antiepileptic drugs. BIS-001 appeared to be well tolerated in these animals.
“BIS-001 demonstrated a high level of efficacy in these models of extremely hard-to-treat epilepsy, eliminating all seizures in most animals and maintaining efficacy over repeat administration, at dose levels we are optimistic will be effective and well tolerated in patients with our new extended-release formulation,” said Dr. Stephen Collins, president and CEO of Biscayne Pharmaceuticals. “We are encouraged by these promising results in a model of devastating childhood epilepsy as we prepare to initiate a Phase 1b clinical trial of BIS-001 in another population with difficult-to-treat seizures—adults with refractory complex partial epilepsy.”
“The active ingredient of BIS-001 is huperzine A, an acetylcholinesterase (AChE) inhibitor that has a long history of safe use in Chinese medicine,” Collins continued. “It also has exhibited the cognition-enhancing properties seen with some other AChE drugs, but has demonstrated much better central nervous system and systemic tolerability and safety than currently available agents. We will be assessing whether BIS-001 supports improved cognition in epilepsy patients, and at the least, we expect it to be devoid of the detrimental effects on cognition seen with many existing antiepileptic drugs. We are eager to test BIS-001 in a variety of conditions, given the high unmet therapeutic need that exists across the spectrum of seizure disorders.”
Biscayne expects to advance BIS-001 into a Phase 1b study in adults in mid-2017, and if all goes well, to proceed to a Phase 2 study shortly thereafter. Clinical trials in children will commence after successful completion of FDA-required juvenile animal safety testing.
Dr. Steven Schachter, professor of neurology at Harvard Medical School, is a scientific co-founder of Biscayne and a co-author of the new study, and commented, “We are eager to test BIS-001 in clinical trials to see if the dramatic elimination of seizures observed in these animals can be replicated in patients, who are in great need of better treatment options.”

Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

DDN Magazine May 2024

Latest Issue  

• Volume 20 • Issue 3 • May 2024

May 2024

May 2024 Issue